PT3288379T - Composições de péptido e métodos de utilização - Google Patents
Composições de péptido e métodos de utilizaçãoInfo
- Publication number
- PT3288379T PT3288379T PT167898303T PT16789830T PT3288379T PT 3288379 T PT3288379 T PT 3288379T PT 167898303 T PT167898303 T PT 167898303T PT 16789830 T PT16789830 T PT 16789830T PT 3288379 T PT3288379 T PT 3288379T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- peptide compositions
- peptide
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155711P | 2015-05-01 | 2015-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3288379T true PT3288379T (pt) | 2022-02-08 |
Family
ID=57217771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167898303T PT3288379T (pt) | 2015-05-01 | 2016-04-29 | Composições de péptido e métodos de utilização |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10508134B2 (enExample) |
| EP (3) | EP4623925A2 (enExample) |
| JP (2) | JP6884755B2 (enExample) |
| KR (2) | KR20240046280A (enExample) |
| CN (2) | CN113651873B (enExample) |
| AU (1) | AU2016258837B2 (enExample) |
| CA (1) | CA2984154A1 (enExample) |
| CY (1) | CY1124911T1 (enExample) |
| DK (1) | DK3288379T3 (enExample) |
| EA (2) | EA035293B1 (enExample) |
| ES (1) | ES2906173T3 (enExample) |
| HR (1) | HRP20220138T1 (enExample) |
| HU (1) | HUE057883T2 (enExample) |
| LT (1) | LT3288379T (enExample) |
| MX (1) | MX387317B (enExample) |
| PL (1) | PL3288379T3 (enExample) |
| PT (1) | PT3288379T (enExample) |
| RS (1) | RS62866B1 (enExample) |
| SI (1) | SI3288379T1 (enExample) |
| SM (1) | SMT202200069T1 (enExample) |
| WO (1) | WO2016178993A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6884755B2 (ja) * | 2015-05-01 | 2021-06-09 | オーエヌエル セラピューティクス，インコーポレーテッド | ペプチド組成物および使用方法 |
| EP3768301A4 (en) * | 2018-03-20 | 2022-06-08 | ONL Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR FAS INHIBITION |
| AU2019288296B2 (en) * | 2018-06-19 | 2022-11-24 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| CN115119501A (zh) * | 2019-12-18 | 2022-09-27 | 细胞疗法有限责任公司 | 包含神经营养剂、凋亡信号传导片段抑制剂（FAS）或FAS配体（FASL）抑制剂、肿瘤坏死因子-α（TNF-α）或TNF受体抑制剂、线粒体肽、寡核苷酸、趋化因子抑制剂或半胱氨酸-天冬氨酸蛋白酶抑制剂的药物递送系统 |
| WO2022266127A1 (en) * | 2021-06-15 | 2022-12-22 | Onl Therapeutics, Inc. | Methods and compositions for treating ocular disorders and diseases |
| JP2024525805A (ja) * | 2021-07-13 | 2024-07-12 | オーエヌエル セラピューティクス，インク． | 眼の疾患および障害における視機能を改善するための方法および組成物 |
| WO2023129766A1 (en) * | 2021-12-27 | 2023-07-06 | Onl Therapeutics, Inc. | Sfasl for inhibiting rpe cell death and associated disorders |
| WO2024031022A2 (en) * | 2022-08-05 | 2024-02-08 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| WO2024031024A1 (en) * | 2022-08-05 | 2024-02-08 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| WO2024220669A1 (en) * | 2023-04-19 | 2024-10-24 | Onl Therapeutics, Inc. | Methods and compositions for treating rnfl thinning |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5532123A (en) * | 1990-07-11 | 1996-07-02 | New York University | Receptor-type phosphotyrosine phosphatase-γ |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| JP3187201B2 (ja) * | 1992-05-14 | 2001-07-11 | 三共株式会社 | Ｃ末端にプロリンアミドを有するペプチドの製法 |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| JP3460863B2 (ja) | 1993-09-17 | 2003-10-27 | 三菱電機株式会社 | 半導体装置の製造方法 |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6001962A (en) | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| US7091047B2 (en) * | 1997-05-23 | 2006-08-15 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity |
| US6363020B1 (en) | 1999-12-06 | 2002-03-26 | Virage Logic Corp. | Architecture with multi-instance redundancy implementation |
| US6480428B2 (en) | 2000-12-19 | 2002-11-12 | Winbond Electronics Corporation | Redundant circuit for memory device |
| EP1730186A2 (en) * | 2004-03-31 | 2006-12-13 | Xencor, Inc. | Bmp-7 variants with improved properties |
| EP1737483A2 (en) | 2004-04-23 | 2007-01-03 | University of Pittsburgh of the Commonwealth System of Higher Education | Cell death modulation via antagonists of fasl and fas activation |
| WO2006121963A2 (en) * | 2005-05-10 | 2006-11-16 | Alcon, Inc. | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders |
| EP1956906A4 (en) * | 2005-11-09 | 2009-12-30 | Combinatorx Inc | METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES |
| US20080280834A1 (en) | 2005-12-01 | 2008-11-13 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds and methods for inhibiting apoptosis |
| WO2009086131A1 (en) * | 2007-12-21 | 2009-07-09 | Stryker Corporation | Bmp mutants with decreased susceptibility to noggin |
| US8343931B2 (en) * | 2009-03-03 | 2013-01-01 | The Regents Of The University Of Michigan | Methods of inhibiting photoreceptor apoptosis |
| JP2010254672A (ja) * | 2009-03-30 | 2010-11-11 | Santen Pharmaceut Co Ltd | ＪＮＫ（ｃ−Ｊｕｎアミノ末端キナーゼ）阻害ペプチドを有効成分として含有する網膜疾患の予防または治療剤 |
| EP2462128B1 (en) * | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| BR112013021494B1 (pt) | 2011-02-22 | 2021-09-08 | California Institute Of Technology | Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo |
| US9381261B2 (en) * | 2011-06-06 | 2016-07-05 | Kineta One, Llc | SHK-based pharmaceutical compositions and methods of manufacturing and using the same |
| WO2013106909A1 (en) | 2012-01-18 | 2013-07-25 | Governing Council Of The University Of Toronto | Novel peptides and methods and uses thereof for preventing retinal disorders |
| JP6087429B2 (ja) * | 2012-06-21 | 2017-03-01 | ハノル バイオファーマ カンパニー リミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． | 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途 |
| CA2890238A1 (en) * | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| JP2018510359A (ja) | 2015-02-05 | 2018-04-12 | イミューンアレイ ユーエスエイ インコーポレイテッド | 脳損傷または神経変性を診断するための方法および組成物 |
| US20190201500A1 (en) | 2015-05-01 | 2019-07-04 | Onl Therapeutics, Inc. | Compositions and methods of fas inhibition |
| JP6884755B2 (ja) * | 2015-05-01 | 2021-06-09 | オーエヌエル セラピューティクス，インコーポレーテッド | ペプチド組成物および使用方法 |
| CN110177577A (zh) | 2016-07-05 | 2019-08-27 | 马萨诸塞大学 | Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法 |
| EP3642229A1 (en) | 2017-06-21 | 2020-04-29 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
| EP3768301A4 (en) | 2018-03-20 | 2022-06-08 | ONL Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR FAS INHIBITION |
| AU2019288296B2 (en) | 2018-06-19 | 2022-11-24 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
-
2016
- 2016-04-29 JP JP2018508624A patent/JP6884755B2/ja active Active
- 2016-04-29 EA EA201792399A patent/EA035293B1/ru unknown
- 2016-04-29 CN CN202110665678.1A patent/CN113651873B/zh active Active
- 2016-04-29 EP EP25186051.6A patent/EP4623925A2/en active Pending
- 2016-04-29 KR KR1020247010090A patent/KR20240046280A/ko not_active Ceased
- 2016-04-29 ES ES16789830T patent/ES2906173T3/es active Active
- 2016-04-29 DK DK16789830.3T patent/DK3288379T3/da active
- 2016-04-29 PL PL16789830T patent/PL3288379T3/pl unknown
- 2016-04-29 RS RS20220095A patent/RS62866B1/sr unknown
- 2016-04-29 HR HRP20220138TT patent/HRP20220138T1/hr unknown
- 2016-04-29 KR KR1020177034366A patent/KR102652804B1/ko active Active
- 2016-04-29 CA CA2984154A patent/CA2984154A1/en active Pending
- 2016-04-29 LT LTEPPCT/US2016/030098T patent/LT3288379T/lt unknown
- 2016-04-29 US US15/570,948 patent/US10508134B2/en active Active
- 2016-04-29 CN CN201680038258.8A patent/CN107708416B/zh active Active
- 2016-04-29 SI SI201631458T patent/SI3288379T1/sl unknown
- 2016-04-29 MX MX2017014075A patent/MX387317B/es unknown
- 2016-04-29 PT PT167898303T patent/PT3288379T/pt unknown
- 2016-04-29 EA EA202090184A patent/EA202090184A3/ru unknown
- 2016-04-29 AU AU2016258837A patent/AU2016258837B2/en active Active
- 2016-04-29 EP EP16789830.3A patent/EP3288379B1/en active Active
- 2016-04-29 WO PCT/US2016/030098 patent/WO2016178993A1/en not_active Ceased
- 2016-04-29 EP EP21200594.6A patent/EP3997981A1/en not_active Withdrawn
- 2016-04-29 HU HUE16789830A patent/HUE057883T2/hu unknown
- 2016-04-29 SM SM20220069T patent/SMT202200069T1/it unknown
-
2019
- 2019-11-04 US US16/673,513 patent/US10829518B2/en active Active
-
2020
- 2020-10-06 US US17/064,495 patent/US11597749B2/en active Active
-
2021
- 2021-05-12 JP JP2021080927A patent/JP2021120400A/ja active Pending
-
2022
- 2022-02-02 CY CY20221100088T patent/CY1124911T1/el unknown
-
2023
- 2023-01-24 US US18/159,021 patent/US12258425B2/en active Active
-
2025
- 2025-02-14 US US19/054,490 patent/US20250346631A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL274276A (en) | CASZ preparations and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| IL257307B (en) | Transgenic crispr–cas9 preparations and methods of use | |
| PL3298043T3 (pl) | Kompozycje polipeptydów SIRP i sposoby zastosowania | |
| ZA201707981B (en) | Compositions of obeticholic acid and methods of use | |
| IL251834A0 (en) | Pharmaceutical compositions containing peptide variants and methods of using them | |
| IL284236A (en) | Modifications and uses of conotoxin peptides | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| ZA201701909B (en) | Trichoderma compositions and methods of use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| SMT202200069T1 (it) | Composizioni peptidiche e metodi di utilizzo | |
| IL256381A (en) | Cryo-deposit preparations and methods for their preparation | |
| IL256843B (en) | Cleaning products and methods of using them | |
| IL257458A (en) | dpep-1 binding compositions and methods of use | |
| SG11201803284YA (en) | Novel method of use and compositions | |
| IL261794A (en) | Preparations and methods for using them | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| IL247448A0 (en) | Peptides and methods of use |